Table 2.
(A) HAM-D-17 and CRP descriptive statistics.
| Baseline | n | Week 4 | n | Baseline vs Week 4 statistics (bootstrapped) | |
|---|---|---|---|---|---|
| HAM-D-17, mean (SD) | |||||
| Minocycline | 19.06 (3.45) | 18 | 13.44 (5.17) | 18 | t = 3.74 p = 0.008 |
| Placebo | 17.00 (3.26) | 21 | 14.10 (5.59) | 21 | t = 3.43 p = 0.003 |
| CRP+/M | 21.50 (2.59) | 6 | 9.5 (5.32) | 6 | t = 4.55 p = 0.02 |
| CRP+/P | 16.08 (2.91) | 12 | 12.58 (5.45) | 12 | t = 2.79 p = 0.03 |
| CRP-/M | 17.83 (3.24) | 12 | 15.42 (3.36) | 12 | t = 2.61 p = 0.03 |
| CRP-/P | 18.22 (4.36) | 9 | 16.11 (5.42) | 9 | t = 1.94 p = 0.11 |
| hsCRP, mean (SD) | |||||
| Minocycline | 3.13 (2.52) | 18 | 3.30 (3.24) | 17 | t = 0.41 p = 0.70 |
| Placebo | 4.49 (5.20) | 21 | 4.03 (3.53) | 21 | t = 0.52 p = 0.61 |
| CRP+/M | 5.68 (2.95) | 6 | 5.13 (4.84) | 6 | All p > 0.05 |
| CRP+/P | 6.62 (6.11) | 12 | 5.86 (3.72) | 12 | |
| CRP-/M | 1.85 (0.72) | 12 | 2.30 (1.39) | 11 | |
| CRP-/P | 1.75 (0.62) | 9 | 1.59 (0.58) | 9 | |
| (B) Proportions of responders and non-responders by groups | |||||
|---|---|---|---|---|---|
| HAM-D-17 improvement <25% | n | HAM-D-17 improvement ≥25% | n | Statistics | |
| CRP+/M | 16.7% | 1 | 83.3% | 5 | X2 = 8.27 p = 0.04 |
| CRP+/P | 41.7% | 5 | 58.3% | 7 | |
| CRP-/M | 75.0% | 9 | 25.0% | 3 | |
| CRP-/P | 77.8% | 7 | 22.2% | 2 | |
HAM-D-17 Hamilton Depression Rating Scale, hsCRP high sensitivity C-reactive protein (analysis conducted with logarithmic CRP), CRP+ baseline hsCRP levels ≥ 3 mg/L, CRP− baseline hsCRP levels < 3 mg/L, M Minocycline, P Placebo.
Bold means that the results are statistically significant.